Industry
Biotechnology
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Loading...
Open
1.79
Mkt cap
63M
Volume
508K
High
2.12
P/E Ratio
-1.04
52-wk high
8.89
Low
1.79
Div yield
N/A
52-wk low
1.00
Portfolio Pulse from Benzinga Insights
October 18, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:11 pm
Portfolio Pulse from Chris Katje
October 02, 2024 | 8:18 pm
Portfolio Pulse from Vandana Singh
September 13, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 13, 2024 | 9:42 am
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:10 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 8:09 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 11:57 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.